DSSG Group: Lung

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy Doublet and/or an Immune Checkpoint Inhibitor, or EGFR TKI (if harbouring EGFR TKI activating mutation)

previously treated metastatic NSCLC with a KRAS G12C mutation.

To evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Advanced/Metastatic Non-Small Cell Lung Cancer

The objective of this trial is to confirm if participants with diagnosed NSCLC could benefit from niraparib plus pembrolizumab versus placebo plus pembrolizumab with respect to progression free survival and overall survival.

Participants with previously untreated Stage IV Non-Small Cell Lung Cancer.

The objective of the trial is to confirm the dose safety of combination relatlimab and nivolumab plus chemo and to compare the progression free survival for patients with untreated stage IV Non-Small Cell Lung Cancer or Recurrent Non-small Cell Lung Cancer.

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).

Participants with previously untreated Locally Advanced Non-Small Cell Lung Cancer.

This study is looking at adding nivolumab to chemoradiotherapy and comparing it to chemoradiotherapy alone. It is also comparing 3 different immunotherapy treatments to have after these first treatments.

inoperable, early stage, high-risk ultracentrally located lung tumours.

The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy.

thoracic cancer and a COVID infection

This registry collects data on patients who have a thoracic cancer and are infected with COVID-19

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).